Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9
- PMID: 20490286
- PMCID: PMC2873634
- DOI: 10.1155/2010/986596
Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9
Abstract
Our immune defense depends on two specialized armed forces. The innate force acts as an alarm mechanism that senses changes in the microenvironment through the recognition of common microbial patterns by Toll-like receptors (TLR) and NOD proteins. It rapidly generates an inflammatory response aimed at neutralizing the intruder at the mucosal checkpoint. The innate arm also communicates this message with more specialized adaptive forces represented by pathogen-specific B cells and T cells. Interestingly, B cells also express some innate sensors, like TLR7 and TLR9, and may respond to bacterial hypomethylated CpG motifs and single-stranded RNA viruses. Intracellular nucleic acid sensing TLRs play an important role in the pathogenesis of Systemic Lupus Erythematosus (SLE). In this review, we describe recent achievements in the development of oligonucleotide-(ODN)-based inhibitors of TLR9 and/or TLR7 signaling. We categorize these novel therapeutics into Classes G, R, and B based on their cellular and molecular targets. Several short ODNs have already shown promise as pathway-specific therapeutics for animal lupus. We envision their future use in human SLE, microbial DNA-dependent sepsis, and in other autoinflammatory diseases.
Figures

Similar articles
-
Guanine-modified inhibitory oligonucleotides efficiently impair TLR7- and TLR9-mediated immune responses of human immune cells.PLoS One. 2015 Feb 19;10(2):e0116703. doi: 10.1371/journal.pone.0116703. eCollection 2015. PLoS One. 2015. PMID: 25695778 Free PMC article.
-
Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus.J Exp Med. 2005 Oct 17;202(8):1131-9. doi: 10.1084/jem.20050914. J Exp Med. 2005. PMID: 16230478 Free PMC article.
-
Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo.Mol Pharmacol. 2014 Mar;85(3):429-40. doi: 10.1124/mol.113.089821. Epub 2013 Dec 16. Mol Pharmacol. 2014. PMID: 24342772
-
Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus.Clin Exp Immunol. 2010 Aug;161(2):208-22. doi: 10.1111/j.1365-2249.2010.04176.x. Epub 2010 May 7. Clin Exp Immunol. 2010. PMID: 20456414 Free PMC article. Review.
-
Recognition of nucleic acid and nucleic acid analogs by Toll-like receptors 7, 8 and 9.Immunobiology. 2008;213(3-4):315-28. doi: 10.1016/j.imbio.2007.10.010. Epub 2007 Nov 28. Immunobiology. 2008. PMID: 18406377 Review.
Cited by
-
Extracellular Nucleic Acids Present in the Candida albicans Biofilm Trigger the Release of Neutrophil Extracellular Traps.Front Cell Infect Microbiol. 2021 May 26;11:681030. doi: 10.3389/fcimb.2021.681030. eCollection 2021. Front Cell Infect Microbiol. 2021. PMID: 34123878 Free PMC article.
-
Dual Toll-Like Receptor Targeting Liposomal Spherical Nucleic Acids.Bioconjug Chem. 2019 Mar 20;30(3):944-951. doi: 10.1021/acs.bioconjchem.9b00047. Epub 2019 Mar 4. Bioconjug Chem. 2019. PMID: 30830754 Free PMC article.
-
In vivo TLR9 inhibition attenuates CpG-induced myocardial dysfunction.Mediators Inflamm. 2013;2013:217297. doi: 10.1155/2013/217297. Epub 2013 Apr 10. Mediators Inflamm. 2013. PMID: 23690658 Free PMC article.
-
Targeting apoptosis in autoimmune hepatitis.Dig Dis Sci. 2014 Dec;59(12):2890-904. doi: 10.1007/s10620-014-3284-2. Epub 2014 Jul 20. Dig Dis Sci. 2014. PMID: 25038736 Review.
-
Sex differences in monocyte activation in systemic lupus erythematosus (SLE).PLoS One. 2014 Dec 8;9(12):e114589. doi: 10.1371/journal.pone.0114589. eCollection 2014. PLoS One. 2014. PMID: 25485543 Free PMC article.
References
-
- Messina JP, Gilkeson GS, Pisetsky DS. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. Journal of Immunology. 1991;147(6):1759–1764. - PubMed
-
- Krieg AM, Yi A-K, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995;374(6522):546–549. - PubMed
-
- Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annual Review of Immunology. 2002;20:709–760. - PubMed
-
- Tokunaga T, Yamamoto H, Shimada S, et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. Journal of the National Cancer Institute. 1984;72(4):955–962. - PubMed
-
- Yamamoto S, Yamamoto T, Kataoka T, Kuramoto E, Yano O, Tokunaga T. Unique palindromic sequences in synthetic oligonucleotides are required to induce INF and augment INF-mediated natural killer activity. Journal of Immunology. 1992;148(12):4072–4076. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources